Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
